Vegetrose® (Vegetrox)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePropoxanePropoxane
Similar drugsTo uncover
  • Vegetrose®
    pills inwards 
    FARMAMED, LLC     Russia
  • Propoxane
    pills inwards 
    PROFIT FARM, LLC     Russia
    • Dosage form: & nbsppills
    Composition:

    1 tablet contains:

    active substance: propoxane hydrochloride 0.015 g;

    Excipients: lactose monohydrate 0.078 g, potato starch 0.005 g, talc 0.001 g, magnesium stearate 0.001 g.

    Description:Round biconvex tablets white or white with a yellowish hue.
    Pharmacotherapeutic group:Alpha-blocker
    ATX: & nbsp

    C.02.C.A   Alpha-blockers

    Pharmacodynamics:

    Proroxane has antihypertensive and antipruritic effect. It blocks postsynaptic alpha 1 and presynaptic alpha 2-adrenergic receptors, regardless of their localization site. Has a peripheral and central influence. Reduces the sensitivity of adrenoreceptors to adrenaline, changing the permeability of cell membranes. Reduces the intensity of stimulation of hypothalamic structures, reducing the release of tropic hormones, hormones of peripheral glands. It reduces the transmission of adrenergic vasoconstrictor impulses, eliminates spasm and expands peripheral vessels, especially arterioles and precapillaries. Improves blood circulation of muscles, skin, mucous membranes.Suppresses the excitability of the diencephalic structures of the brain and regulates the tone of the sympathoadrenal system.

    Pharmacokinetics:

    Ingestion prophet well absorbed in the gastrointestinal tract, effective concentration is achieved after 30-40 minutes and persists for 3-4 hours. Binding to plasma proteins is weak. The drug has a large volume of distribution, it quickly penetrates into various tissues and fluids, including cerebrospinal fluid.

    Well penetrates through the histohematological barriers, including blood-brain. Selectively retained in the hypothalamus, the posterior region of which contains predominantly noradrenergic neurons. It is excreted mainly by the kidneys. About 70% of the administered dose is excreted by the kidneys in the first 24 hours.

    In animal experiments with intraperitoneal administration, the elimination half-life was not established, while in the blood plasma, less than 5% of the administered dose of the drug remained in the blood plasma after 1 hour, and after 2 hours - only traces. In the brain, after 22 hours 22% were detected, after 2 hours, 6% of the maximum concentration. Also, in experiments with labeled carbon with propoxane, it was shown that the products of its metabolism are able to linger for a long time (up to 10 days) in various organs and tissues (plasma, brain, liver, kidneys).

    Indications:

    - Somatoform autonomic dysfunction, proceeding according to the sympathoadrenal type, including with increasing blood pressure (as a symptomatic agent in the complex therapy);

    - allergic dermatitis (as a symptomatic agent in the complex therapy for the relief of itching).

    Contraindications:

    - Hypersensitivity to the active ingredient and auxiliary components of the drug;

    - cardiac ischemia (II-IV functional class);

    - circulatory insufficiency II-III degree;

    - arterial hypotension;

    - cardiogenic shock;

    bradycardia;

    - myocardial infarction;

    - severe atherosclerosis;

    - expressed cerebrovascular insufficiency (including strokes, transient ischemic attacks in the anamnesis);

    - age under 18 years (effectiveness and safety not established);

    - Lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome.

    Carefully:

    Elderly age, ischemic heart disease, arrhythmia, peptic ulcer.

    It is recommended to monitor the concentration of glucose in the blood (possibly raising the level of endogenous insulin).

    Pregnancy and lactation:

    The use of VEGETROX® is contraindicated in pregnancy and during breastfeeding due to insufficient data on efficacy and safety.

    Dosing and Administration:

    With somatoform autonomic dysfunction, which proceeds according to the sympathoadrenal type in the complex therapy, 15-30 mg (1-2 tablets) are administered 2-3 times a day 2-3 times a day. The duration of treatment is determined by the attending physician.

    When allergic dermatitis in the complex therapy is recommended to appoint 15-30 mg (1-2 tablets) inside before going to bed. The duration of treatment is determined by the attending physician.

    Side effects:

    The frequency of development of adverse reactions is given according to the classification of the World Health Organization (WHO): very often more than 1/10, often more than 1/100 and less than 1/10, infrequently more than 1/1000 and less than 1/100, rarely more than 1 / 10000 and less than 1/1000, very rarely - less than 1/10000; the frequency is unknown (according to available data, it is not possible to determine the frequency of development).

    From the cardiovascular system: frequency unknown - arterial hypotension, bradycardia, occurrence of angina attacks in predisposed patients, orthostatic hypotension, arrhythmias, dizziness, hyperemia of the skin, nasal congestion.

    From the gastrointestinal tract: frequency unknown - diarrhea, increased secretion of hydrochloric acid in the stomach.

    From the skin: frequency is unknown - allergic reactions.

    If any of the side effects listed in the manual are aggravated or you notice any other side effects not listed in the instructions, inform the doctor about it.

    Overdose:

    Symptoms: bradycardia, a sharp decrease in blood pressure, orthostatic collapse.

    Treatment: symptomatic, aimed at maintaining vital functions.

    Interaction:

    Simultaneous use of propoxane and epinephrine can lead to a decrease in the effectiveness of the latter (the development of the depressor effect in place of the pressor one). Simultaneous use with antihypertensive drugs leads to a mutual enhancement of the effect of lowering blood pressure.

    Strengthens the action of neuroleptics (derivatives of phenothiazine, butyrophenone, diphenylbutylpiperidine, thioxanthene).

    Against a background of joint application with novocainamide, it is possible to reduce the stroke volume of the heart.

    Special instructions:

    Features of the drug at the first admission:

    When taking the first dose of the drug, a sharp drop in blood pressure, fainting, headache, weakness, palpitations and deterioration of the subjective state (the "first-dose phenomenon") is possible, which is not an excuse for discontinuing the drug, since this effect disappears upon repeated admission. Also note drowsiness, a rapidly passing sensation of numbness of the tongue. In addition, it is recommended to monitor the concentration of glucose in the blood because of the possible increase in the level of endogenous insulin. In this connection, it is necessary to start treatment under the supervision of a doctor with a minimum effective dose and to comply with bed rest after taking the drug for 6-8 hours.

    Effect on the ability to drive transp. cf. and fur:

    During the period of drug treatment it is not recommended to drive vehicles and engage in other potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions.

    Form release / dosage:Tablets 15 mg.
    Packaging:

    10 tablets per contour cell packaging made of polyvinylchloride film and aluminum foil. For 1, 2, 3, 4 or 5 contour mesh packages together with instructions for the use of medicinal products for medical use in a pack of cardboard.

    Or 10, 20 or 30 tablets in a tube of polymeric polyethylene, corked with a stopper. The label is self-adhesive on the test-tube. 1 tube together with instructions for the use of a medicinal product for medical use in a pack of cardboard.

    Or 30, 40, 50 or 100 tablets in a plastic polymer can with a lid equipped with a compensator. The label is self-adhesive on the can. 1 bank together with instructions for the use of medicinal products for medical use in a pack of cardboard.

    Storage conditions:

    Store in a dark place at a temperature of no higher than 30 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-004403
    Date of registration:03.08.2017
    Expiration Date:03.08.2022
    The owner of the registration certificate:FARMAMED, LLC FARMAMED, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp01.09.2017
    Illustrated instructions
      Instructions
      Up